Update from Biogen
In a community statement, Biogen shared their plans to initiate the BRAVE study, a global Phase 3 study evaluating the effects and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 – 15 years. Biogen stated that the BRAVE study will initially include six sites across the United States, with the first two sites expected to open enrollment this summer and the remainder throughout this year. This study is planned to have sites globally.
